Patents Assigned to Novartis Vaccines & Diagnostics SRL.
-
Patent number: 9102729Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: GrantFiled: April 29, 2014Date of Patent: August 11, 2015Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Publication number: 20150174234Abstract: Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 ?g per influenza virus strain per ml. Components (i) and (ii) can be presented in kit form.Type: ApplicationFiled: December 17, 2014Publication date: June 25, 2015Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventor: Mario CONTORNI
-
Patent number: 9056912Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: September 9, 2013Date of Patent: June 16, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 9040055Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: June 7, 2013Date of Patent: May 26, 2015Assignee: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventor: Francesco Berti
-
Patent number: 8945589Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.Type: GrantFiled: September 15, 2004Date of Patent: February 3, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Publication number: 20140356389Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Publication number: 20140302087Abstract: When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Applicant: Novartis Vaccines and Diagnostics, SRLInventor: Mario CONTORNI
-
Publication number: 20140294884Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.Type: ApplicationFiled: March 24, 2014Publication date: October 2, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Maria ARICO, Maurizio COMANDUCCI
-
Publication number: 20140248312Abstract: Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Rino RAPPUOLI, Derek O'HAGAN, Giuseppe DEL GIUDICE
-
Publication number: 20140234363Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be usedin medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Patent number: 8802111Abstract: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.Type: GrantFiled: November 22, 2011Date of Patent: August 12, 2014Assignee: Novartis Vaccines and Diagnostics, SRLInventor: Mario Contorni
-
Patent number: 8758764Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: GrantFiled: February 17, 2006Date of Patent: June 24, 2014Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter InstituteInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20140037671Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: ApplicationFiled: September 9, 2013Publication date: February 6, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 8529913Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: March 2, 2012Date of Patent: September 10, 2013Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 8513392Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: February 1, 2006Date of Patent: August 20, 2013Assignee: Novartis Vaccines and Diagnostics SRLInventor: Francesco Berti
-
Patent number: 8481057Abstract: The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from Chlamydia trachomatis that are expressed on the cell surface and so are ideal for use in immunization as well as combinations of these antigens.Type: GrantFiled: December 19, 2006Date of Patent: July 9, 2013Assignee: Novartis Vaccines & Diagnostics SRLInventors: Guido Grandi, Lehutova Livia
-
Patent number: 8476032Abstract: Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fHBp) are provided, as well as non-human animal models of Neisserial infection.Type: GrantFiled: August 26, 2009Date of Patent: July 2, 2013Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, The University of MassachusettsInventors: Dan M. Granoff, JoAnne Welsch, Sanjay Ram
-
Patent number: 8470340Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.Type: GrantFiled: September 2, 2009Date of Patent: June 25, 2013Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, Universita degli Studi del MoliseInventors: Peter Beernink, Franco Felici, Dan M. Granoff
-
Patent number: 8398986Abstract: An ADP-ribosylating toxin from Listeria monocytogenes is disclosed, together with mutant toxins and uses therefor. There is only a low level of sequence identity between this toxin and known toxins such as the iota toxin from Clostridium perfringens.Type: GrantFiled: April 8, 2004Date of Patent: March 19, 2013Assignee: Novartis Vaccines and Diagnostics SRLInventor: Vega Masignani
-
Publication number: 20130004531Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRLInventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker